Skip to main content
Show — Main navigation
Hide — Main navigation
Hair & Scalp
Cutaneous & COVID
Expert Insights in Derm
AAD Summer Meeting
SDPA Fall Conference
AAD VMX 2020
GW Advances in Acne
San Diego Dermatology Symposium
Centers of Excellence
FDA Approves New Psoriasis Treatment for Adolescents
The FDA approved a new foam treatment for adolescents with plaque psoriasis on the scalp and body.
FDA Approves Enbrel Biosimilar
The FDA has approved a second biosimilar to etanercept for the treatment of various autoimmune conditions.
FDA Approves Topical Therapy for Psoriasis
The FDA has approved a new topical therapy for the treatment of plaque psoriasis in adult patients.
FDA Approves New Therapy for Psoriasis
The FDA approved a new biologic for the treatment of moderate to severe plaque psoriasis.
FDA Approves Biologic for Adolescents with Eczema
The FDA approved dupiliumab for the treatment of moderate to severe atopic dermatitis in adolescents.
FDA Approves New Biosimilar
The FDA has approved a new biosimilar for patients with various autoimmune diseases, including psoriasis and psoriatic arthritis.
FDA Approves New Therapy for Advanced SCC
The FDA approved the first treatment specifically for patients with advanced cutaneous squamous cell carcinoma.
FDA Approves New Topical for Acne
The FDA has approved a new topical, once-daily lotion for the treatment of acne vulgaris in patients aged 9 years and older.
Combination Therapy Approved by FDA for Melanoma
The FDA has approved a combination therapy to treat unresectable or metastatic melanoma with BRAF mutations.
FDA Approves Inclusion of New Evidence for Secukinumab
The FDA has approved the inclusion of new evidence to the prescribing label for secukinumab for the treatment of psoriatic arthritis.
Stay in the know.
The Dermatologist Newsletter
Back to Top